Wednesday, October 14, 2026

Private Credit Funds Lock Withdrawals as Asset Sales Hit Discounts, Raising Valuation Concerns

Blue Owl halted quarterly withdrawals from its retail fund while New Mountain Finance shares plunged to 2020 lows after discounted asset sales. The convergence of withdrawal restrictions, dividend cuts at FS KKR Capital, and defensive analyst positioning suggests private credit portfolios may face hidden credit deterioration masked by mark-to-model valuations.

Private Credit Funds Lock Withdrawals as Asset Sales Hit Discounts, Raising Valuation Concerns
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Blue Owl Capital halted quarterly withdrawals from its retail private credit fund, joining a wave of liquidity restrictions across the $1.7 trillion private credit sector. The move coincides with New Mountain Finance shares dropping to March 2020 levels following discounted asset sales.

FS KKR Capital cut dividends while New Mountain Finance sold assets below reported valuations, triggering concerns about net asset value accuracy. Bank of America issued a buy rating on Blue Owl "amid misinformation," language that suggests defensive positioning rather than fundamental conviction.

The pattern reveals stress across business development companies. Withdrawal gates prevent redemptions when secondary market prices diverge from reported NAVs. Mark-to-model valuations allow managers to smooth portfolio values, but asset sales at discounts expose gaps between reported and realizable prices.

Gladstone Capital management said it "feels better about non-accrual names than a year ago" despite challenging M&A valuations—a statement that acknowledges valuation difficulties while claiming improvement. Non-accrual rates and watch list metrics in quarterly BDC filings will test whether optimism matches portfolio reality.

European insurers are distancing themselves from U.S. private credit exposure. Thomas Buberl at AXA stated exposure sits "far below that of rivals." Claire-Marie Coste-Lepoutre at Allianz claimed the insurer feels "very comfortable" with its private credit position. The messaging suggests concern about concentration risk.

Investors should compare reported NAVs against secondary market transaction prices for private credit funds. Covenant violation disclosures in quarterly filings and any changes to independent valuation firms signal deteriorating credit quality before official write-downs appear.

The correlation between withdrawal restriction timing and subsequent portfolio markdowns in previous credit cycles suggests current gates may precede valuation adjustments. Banking sector exposure to private credit through fund investments and warehouse lending creates potential spillover effects if portfolio stress accelerates.

Secondary market pricing for private credit funds trading at discounts to NAV indicates investors doubt reported valuations. The $406 billion BDC sector faces pressure as higher-for-longer rates stress leveraged borrowers while exit valuations compress.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com